Highlights
About
Anticancer Immunotherapy Treatment
Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. The technology is based on the concept of engaging the bodys own immune system and harnessing it against cancer. Efranat has succeeded in engineering a natural vitamin D binding protein into a potent immune modulator to fight cancer and chronic viral diseases. The companys primary product, EF-022, is an immunomodulator that activates macrophages, a group of white blood cells that play a key role in the immune systems defense against cancer. The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body. A test involving 14 dogs with cancer that were treated with EF-022 showed promising results. Efranat is currently conducting a phase 1 clinical trial in human cancer patients with advanced solid tumors at the Sheba Medical Center.
Identity
| Name | Efranat Pharma |
|---|---|
| Slug | efranat |
| Type / kind | startup |
| Crunchbase ID | efranat |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6ph-gKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2018 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Prof. Hillel ve-Khanan Oppenheimer 7, Rehovot, Israel |
Web & social
| https://www.linkedin.com/company/2679683 |
Classifications
Funding
| Total raised | $4.5M |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}